prof. dr. H.M. (Helena) Verkooijen

prof. dr. H.M. (Helena) Verkooijen

Full Professor
prof. dr. H.M. (Helena) Verkooijen
  • Clinical Trial Office

Research Programs




Professor of Evaluation of Image-Guided Treatment, dedicated to improve the life of people with cancer. Committed to full integration of clinical research in routine patient care in order to facilitate undelayed evidence-based implementation of innovations in oncology.

Director of Research at the division of Imaging and Oncology of the UMC Utrecht. Project leader of several international (Horizon) research consortia and academic industrial partnership, head of clinical research office and investigator in a range of (international) scientific studies. Strong background in teaching and development of educational modules at graduate and postgraduate level. Large international academic experience in Europe and Asia. Experienced speaker, moderator, and panel member. 

Within the Division of Imaging and Cancer of the UMC Utrecht, I am responsible for clinical evaluation of innovative cancer treatments, and for evaluating to what extent theoretical benefits of these innovations translate into real benefits for patients. I lead a team of post-doc researchers, PhD students, and (medical) graduate students. I also lead the division’s clinical research office, which is responsible for trial support, data management, IT solutions, quality control and medico-ethical advise (supporting 200 academic researchers).


Side Activities


  • Member Supervisory Board Oogziekenhuis Rotterdam
  • Member evaluation committee Dutch Cancer Foundation
  • Chair Steering Committe Center of Excellence of the Focused Ultrasound Foundation
  • Member Scientific Advisory Board Dutch Expert Centre for Screening
  • Board Member J.M. Fentener van Vlissingen Fonds

Research Output (401)

Patient expectation and experience of MR-guided radiotherapy using a 1.5T MR-Linac

de Mol van Otterloo S R, Westerhoff J M, Leer T, Rutgers R H A, Meijers L T C, Daamen L A, Intven M P W, Verkooijen H M Mar 2024, In: Technical innovations & patient support in radiation oncology. 29 7 p.

Breast cancer patients' needs and perspectives on a one-on-one peer support program:quantitative and qualitative analyses

Jansen Britt Am, Bargon Claudia A, Dinger Tessa L, van den Goor Myra, Postma Emily L, Young-Afat Danny A, Verkooijen Helena M, Doeksen Annemiek 26 Oct 2023, In: Supportive Care in Cancer. 31

Efficacy of indocyanine green fluorescence for the identification of non-palpable breast tumours:systematic review

Jansen Britt A M, Bargon Claudia A, Huibers Anne E, Postma Emily L, Young-Afat Danny A, Verkooijen Helena M, Doeksen Annemiek 1 Oct 2023, In: BJS open. 7 9 p.

Evolution of the MOMENTUM Study for Evidence-Based Implementation of MR-Guided Radiotherapy Using the 1.5 Tesla MR-Linac

Daamen L A, Westerhoff J M, Christodouleas J P, Orrling K, Eggert D, Choudhury A, Fuller C D, van der Heide U, Sahgal A, Schultz C J, Schytte T, Tersteeg JHA, Tree A, Hall W A, Verkooijen H 1 Oct 2023, In: International journal of radiation oncology, biology, physics. 117 , p. e576-e577

Introducing the New Patient Expectations in Spine Oncology Questionnaire

Versteeg Anne L, Gal Roxanne, Charest-Morin Raphaele, Reichl Leilani, Tsang Angela, Aludino Allan, Sahgal Arjun, Verlaan Jorrit-Jan, Fisher Charles G, Verkooijen Helena M 6 Jul 2023, In: Neurosurgery. 93 , p. 1331-1338 8 p.

Realizing the value of complex medical technology:Demonstrating cost-effectiveness is not enough

Hehakaya C., Frederix G. W.J., van der Voort van Zyp J. RN, Grobbee D. E., Verkooijen H. M. Jul 2023, In: Clinical and translational radiation oncology. 41

Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR):protocol of a phase I dose-escalation trial

Verweij Maaike E, Tanaka Max D, Kensen Chavelli M, van der Heide Uulke A, Marijnen Corrie A M, Janssen Tomas, Vijlbrief Tineke, van Grevenstein Wilhelmina M U, Moons Leon M G, Koopman Miriam, Lacle Miangela M, Braat Manon N G J A, Chalabi Myriam, Maas Monique, Huibregtse Inge L, Snaebjornsson Petur, Grotenhuis Brechtje A, Fijneman Remond, Consten Esther, Pronk Apollo, Smits Anke B, Heikens Joost T, Eijkelenkamp Hidde, Elias Sjoerd G, Verkooijen Helena M, Schoenmakers Maartje M C, Meijer Gert J, Intven Martijn, Peters Femke P 15 Jun 2023, In: BMJ Open. 13 , p. 1-10

Defining the role of real-world data in cancer clinical research:The position of the European Organisation for Research and Treatment of Cancer

Saesen Robbe, Van Hemelrijck Mieke, Bogaerts Jan, Booth Christopher M, Cornelissen Jan J, Dekker Andre, Eisenhauer Elizabeth A, Freitas André, Gronchi Alessandro, Hernán Miguel A, Hulstaert Frank, Ost Piet, Szturz Petr, Verkooijen Helena M, Weller Michael, Wilson Roger, Lacombe Denis, van der Graaf Winette T Jun 2023, In: European Journal of Cancer. 186 , p. 52-61 10 p.

The use of red flags during the referral chain of patients surgically treated for symptomatic spinal metastases

van Tol Floris R, Kamm Isabelle M L P, Versteeg Anne L, Suijkerbuijk Karijn P M, Verkooijen Helena M, Oner Cumher, Verlaan Jorrit-Jan Jun 2023, In: Neuro-Oncology Practice. 10 , p. 301-306 6 p.

Timing of rectal cancer surgery after short-course radiotherapy:national database study

Verweij Maaike E, Franzen Jolien, van Grevenstein Wilhelmina M U, Verkooijen Helena M, Intven Martijn P W 12 May 2023, In: The British journal of surgery. 110 , p. 839-845 7 p.

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not